CC BY-NC-ND 4.0 · J Neurol Surg Rep 2017; 78(01): e34-e36
DOI: 10.1055/s-0037-1598112
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Calcified Middle Cranial Fossa Mass

James Botros
1   Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, United States
,
Kimmo Hatanpaa
2   Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, United States
,
Brandon Isaacson
3   Department of Otolaryngology, University of Texas Southwestern Medical Center, Dallas, Texas, United States
,
Samuel L. Barnett
1   Department of Neurological Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, United States
› Author Affiliations
Further Information

Publication History

20 July 2016

21 December 2016

Publication Date:
01 March 2017 (online)

Abstract

A 21-year-old male presented for evaluation of transient loss of consciousness and was found to have a hyperdense mass in the left middle fossa. He underwent craniotomy for tumor resection. Intra- and extradural invasion was noted. Gross total resection was achieved. Pathology demonstrated a densely cellular neoplasm with predominately spindle cell morphology in a collagen-containing stroma, areas of vascular proliferation, focal mineralization, and regions of cartilage formation. High mitotic index and regions of necrosis were seen. Based on the final diagnosis of osteosarcoma, the patient was referred for chemotherapy and radiation. Intracranial osteosarcoma is a nonmeningiomatous mesenchymal tumor. Most osteosarcomas are meningeal-based and supratentorial. Presentation depends on tumor location and may include focal neurologic deficits, cranial neuropathy, seizures, or symptoms of increased intracranial pressure. Given the relative rarity of intracranial osteosarcoma, there are no established guidelines for treatment, and therapy is guided by experience with systemic osteosarcoma. Gross total resection is recommended whenever feasible. Both chemotherapy and radiation therapy are used as adjuvant therapy. Regardless of treatment, osteosarcoma remains a highly aggressive malignancy with a poor prognosis. Morbidity and mortality may be the result of local recurrence or development of pulmonary or skeletal metastasis.

 
  • References

  • 1 Paulus W, Scheithauer BW, Perry A. Mesenchymal, non-meningothelial tumours. In: Louis DN, Ohgaki H, Wiestler OD. , et al, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: International Agency for Research on Cancer; 2007: 173-176
  • 2 Cihan YB, Kaplan B, Deniz K. , et al. Primary calvarial osteosarcoma: a case report. J Neurol Sci (Turkish) 2012; 1: 122-128
  • 3 Prayson RA. Non-glial tumors. In: Prayson RA. , ed. Neuropathology. Philadelphia, PA: Elsevier; 2012: 518-521
  • 4 Ashkan K, Pollock J, D'Arrigo C, Kitchen ND. Intracranial osteosarcomas: report of four cases and review of the literature. J Neurooncol 1998; 40 (01) 87-96
  • 5 Setzer M, Lang J, Turowski B, Marquardt G. Primary meningeal osteosarcoma: case report and review of the literature. Neurosurgery 2002; 51 (02) 488-492 , discussion 492